Unweighted and weighted patient characteristics are included in the propensity score estimation
| . | Before IPW . | After IPW . | ||||
|---|---|---|---|---|---|---|
| HGBL (n = 78) . | DLBCL (n = 354) . | SMD . | HGBL (n = 78) . | DLBCL (n = 77.8) . | SMD . | |
| Age, median (IQR), y | 63 (55.5-68) | 60 (62-67) | 0.292 | 63 (55-68) | 63 (56-68) | 0.010 |
| Sex male, n (%) | 45 (57.7) | 234 (66.1) | 0.174 | 45 (57.7) | 44.8 (57.5) | 0.004 |
| CRP at infusion ≥10, n (%) | 39 (50) | 178 (50.3) | 0.006 | 39 (50) | 38.6 (49.6) | 0.008 |
| ECOG ≥1, n (%) | 31 (39.7) | 146 (41.2) | 0.031 | 31 (39.7) | 30.4 (39) | 0.014 |
| Disease status, refractory, n (%) | 60 (76.9) | 246 (69.5) | 0.168 | 60 (76.9) | 60.3 (77.5) | 0.014 |
| IPI >2, n (%) | 47 (60.3) | 149 (42.1) | 0.370 | 47 (60.3) | 47.1 (60.5) | 0.005 |
| No. of prior lines >2, n (%) | 22 (28.2) | 122 (34.5) | 0.135 | 22 (28.2) | 22.3 (28.6) | 0.009 |
| Previous ASCT, n (%) | 18 (23.1) | 102 (28.8) | 0.131 | 18 (23.1) | 17.5 (22.4) | 0.015 |
| Response to bridge, n (%) | 0.498 | 0.018 | ||||
| No bridge | 4 (5.1) | 75 (21.2) | 4 (5.1) | 4 (5.1) | ||
| No response | 49 (62.8) | 172 (48.6) | 49 (62.8) | 48.3 (62) | ||
| Response | 25 (32.1) | 107 (30.2) | 25 (32.1) | 25.6 (32.9) | ||
| Bulky disease, n (%) | 33 (42.3) | 110 (31.1) | 0.235 | 33 (42.3) | 31.9 (40.9) | 0.028 |
| CAR T-cell therapy product tisa-cel, n (%) | 40 (51.3) | 182 (51.4) | 0.003 | 40 (51.3) | 39.8 (51.1) | 0.004 |
| Time from leukapheresis to infusion, median (IQR), mo | 1.6 (1.29-2.26) | 1.61 (1.35-2.27) | 0.115 | 1.58 (1.28-2.26) | 1.61 (1.37-2.14) | 0.022 |
| . | Before IPW . | After IPW . | ||||
|---|---|---|---|---|---|---|
| HGBL (n = 78) . | DLBCL (n = 354) . | SMD . | HGBL (n = 78) . | DLBCL (n = 77.8) . | SMD . | |
| Age, median (IQR), y | 63 (55.5-68) | 60 (62-67) | 0.292 | 63 (55-68) | 63 (56-68) | 0.010 |
| Sex male, n (%) | 45 (57.7) | 234 (66.1) | 0.174 | 45 (57.7) | 44.8 (57.5) | 0.004 |
| CRP at infusion ≥10, n (%) | 39 (50) | 178 (50.3) | 0.006 | 39 (50) | 38.6 (49.6) | 0.008 |
| ECOG ≥1, n (%) | 31 (39.7) | 146 (41.2) | 0.031 | 31 (39.7) | 30.4 (39) | 0.014 |
| Disease status, refractory, n (%) | 60 (76.9) | 246 (69.5) | 0.168 | 60 (76.9) | 60.3 (77.5) | 0.014 |
| IPI >2, n (%) | 47 (60.3) | 149 (42.1) | 0.370 | 47 (60.3) | 47.1 (60.5) | 0.005 |
| No. of prior lines >2, n (%) | 22 (28.2) | 122 (34.5) | 0.135 | 22 (28.2) | 22.3 (28.6) | 0.009 |
| Previous ASCT, n (%) | 18 (23.1) | 102 (28.8) | 0.131 | 18 (23.1) | 17.5 (22.4) | 0.015 |
| Response to bridge, n (%) | 0.498 | 0.018 | ||||
| No bridge | 4 (5.1) | 75 (21.2) | 4 (5.1) | 4 (5.1) | ||
| No response | 49 (62.8) | 172 (48.6) | 49 (62.8) | 48.3 (62) | ||
| Response | 25 (32.1) | 107 (30.2) | 25 (32.1) | 25.6 (32.9) | ||
| Bulky disease, n (%) | 33 (42.3) | 110 (31.1) | 0.235 | 33 (42.3) | 31.9 (40.9) | 0.028 |
| CAR T-cell therapy product tisa-cel, n (%) | 40 (51.3) | 182 (51.4) | 0.003 | 40 (51.3) | 39.8 (51.1) | 0.004 |
| Time from leukapheresis to infusion, median (IQR), mo | 1.6 (1.29-2.26) | 1.61 (1.35-2.27) | 0.115 | 1.58 (1.28-2.26) | 1.61 (1.37-2.14) | 0.022 |
IPW, inverse probability weighting; SMD, standardized mean difference.